|
ELMO2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
3.4458999986775E-08 |
| Normal-vs-Stage3 |
1.3785972363678E-11 |
| Normal-vs-Stage4 |
1.17119647313757E-11 |
| Stage1-vs-Stage2 |
7.256000E-01 |
| Stage1-vs-Stage3 |
1.421180E-01 |
| Stage1-vs-Stage4 |
4.065000E-01 |
| Stage2-vs-Stage3 |
1.845440E-01 |
| Stage2-vs-Stage4 |
7.297600E-01 |
| Stage3-vs-Stage4 |
5.587800E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
3.72559999994859E-06 |
| Normal-vs-Asian |
1.68409952649995E-10 |
| Caucasian-vs-AfricanAmerican |
1.326780E-01 |
| Caucasian-vs-Asian |
7.984100E-02 |
| AfricanAmerican-vs-Asian |
8.894600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.10462807976364E-15 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
8.359200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.66133814775094E-16 |
| Normal-vs-Age(41-60Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(61-80Yrs) |
2.06101802291414E-12 |
| Normal-vs-Age(81-100Yrs) |
7.357600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.517000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.091400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.748600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.126800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.227000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.156200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.781400E-01 |
| Classical-VS-Follicular |
6.470300E-02 |
| Classical-VS-Other |
9.289200E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
8.971400E-01 |
| Tall-VS-Other |
5.154000E-01 |
| Tall-VS-Normal |
9.76669999985802E-07 |
| Follicular-VS-Other |
5.370400E-01 |
| Follicular-VS-Normal |
3.12549996994704E-09 |
| Other-VS-Normal |
1.94497000000071E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.44089209850063E-16 |
| Normal-vs-N1 |
3.61819999961099E-07 |
| N0-vs-N1 |
4.679800E-01 |
|
|
